1 BTC
=
- USD
Xilio Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Xilio Therapeutics, Inc. Common Stock
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Market Statistics
Trading Metrics
How to Buy XLO
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy XLO
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesXilio Therapeutics granted non-qualified stock options to purchase 3,257 shares to two new employees at an exercise price of $8.48 per share on April 1, 2026. The options have a ten-year term with a 25% vesting on the first anniversary and remaining 75% vesting monthly over three years, subject to continued employment.
Xilio Therapeutics announced the pricing of an underwritten offering of 74.78 million pre-funded warrants at $0.5349 per warrant, expected to raise approximately $40 million in gross proceeds. The financing was led by existing investor Coastlands Capital and included participation from Gilead Sciences, OrbiMed, and Perceptive Advisors. Proceeds will be used to advance product development and for general corporate purposes.
Xilio Therapeutics will present clinical and preclinical data on tumor-activated immuno-oncology therapies at the Society for Immunotherapy of Cancer's annual meeting in November 2025, highlighting research on vilastobart, efarindodekin alfa, and masked T cell engager programs.
Xilio Therapeutics announced the closing of a $50.0 million public offering, with the potential for up to $150.0 million in total gross proceeds if all warrants are exercised. The financing was co-led by new investors Coastlands Capital and Frazier Life Sciences, and included participation from Gilead Sciences, Logos Capital, and Samsara BioCapital.
Xilio Therapeutics, a clinical-stage biotechnology company, announced a proposed public offering of pre-funded warrants, Series A, B, and C warrants to purchase shares of common stock. The company plans to use the net proceeds to advance the development of its product candidates and for general corporate purposes.